Rising Prevalence Of Infectious Diseases Fueling The Growth Of The Market Due To Increasing Global Travel And Pathogen Spread Is Supporting Development Across The Neutralizing Antibody Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Estimated Growth In Market Size Of The Neutralizing Antibody Market During 2026–2030?

The neutralizing antibody market size has seen significant expansion in recent years. It is anticipated to increase from $257.81 billion in 2025 to $288.51 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.9%. This historical growth can be attributed to elements such as the advent of viral epidemics like sars-cov-2, the creation of initial monoclonal antibody platforms, increased research and development in immunology, the use of antibodies in diagnostic tests, and the reliance on animal-derived polyclonal antibodies.

The neutralizing antibody market size is projected for significant expansion over the coming years. Its value is anticipated to reach $447.16 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.6%. This expansion during the projection period can be attributed to several factors, including progress in fully human and humanized monoclonal antibodies, the development of recombinant polyclonal antibody technology, a growing worldwide need for COVID-19 and influenza treatments, increased partnerships between pharmaceutical and biotechnology firms, and the broadening of antibody research in developing regions. Key trends expected throughout this forecast span encompass increased capital directed towards neutralizing antibody therapeutics, a wider scope of monoclonal and polyclonal antibody development, more applications in viral diagnostics and scientific inquiry, a heightened emphasis on individualized medicine and specific treatments, and stricter regulatory supervision and adherence for antibody manufacturing.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24620&type=smp

Which Strategic Drivers Are Supporting The Neutralizing Antibody Market Development?

An anticipated increase in infectious disease cases is projected to drive expansion within the neutralizing antibody market moving ahead. Such diseases are conditions triggered by detrimental microorganisms like bacteria, viruses, fungi, or parasites, capable of transmitting from one individual to another, either directly or indirectly. The growing occurrence of infectious diseases stems from enhanced global travel, which aids the swift dissemination of pathogens across different regions. Neutralizing antibodies improve the treatment of infectious diseases by precisely identifying and inhibiting pathogens, thereby proving useful in halting disease advancement. These antibodies contribute to better patient results through their provision of accurate and prompt immune defense. As an illustration, the UK Health Security Agency, a UK-based governmental body, reported in February 2024 that instances of tuberculosis (a communicable bacterial infection mainly impacting the lungs) in England climbed to 4,850 in 2023, representing a 10.7% surge from the 4,380 cases recorded in 2022. Consequently, the increased incidence of infectious diseases is fueling the expansion of the neutralizing antibody market.

Which Segment Groups Define The Neutralizing Antibody Market Landscape?

The neutralizing antibody market covered in this report is segmented –

1) By Antibody Type: Monoclonal Antibodies, Polyclonal Antibodies

2) By Target Virus: SARS-CoV-2 (COVID-19), Human Immunodeficiency Viruses (HIV), Influenza, Ebola, Zika, Hepatitis C, Other Target Viruses

3) By Distribution Channel: Direct Sales To End-Users, Distributors, Online Retail, Other Distribution Channels

4) By Application: Therapeutics, Diagnostics, Research And Development

5) By End User: Hospitals And Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, Other End Users

Subsegments:

1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Murine Monoclonal Antibodies

2) By Polyclonal Antibodies: Animal-Derived Polyclonal Antibodies, Recombinant Polyclonal Antibodies, Human Polyclonal Antibody Preparations

What Trends Are Affecting The Growth Of The Neutralizing Antibody Market?

Leading firms within the neutralizing antibody market are concentrating their efforts on creating novel approaches, including long-acting monoclonal neutralizing antibodies, aiming to offer sustained defense against contagious illnesses, cater to the neglected health requirements of at-risk groups, and surmount the drawbacks of conventional vaccines. These long-acting monoclonal neutralizing antibodies are designed proteins engineered to specifically attach to viral antigens with strong affinity, thereby preventing infection. Their extended presence in the body is achieved through modifications in their Fc region, which prolongs their half-life. Differing from typical small-molecule antivirals or vaccines, these antibodies confer passive immunity, eliminating the need for recurrent doses or the body’s own active immune engagement. An illustrative example occurred in June 2025, when Merck & Co. Inc, a pharmaceutical company based in the US, introduced clesrovimab-cfor. This product is a long-acting monoclonal neutralizing antibody, which had received approval from the U.S. FDA. It is classified as a fully human IgG1κ antibody, specifically designed to target the fusion (F) protein of respiratory syncytial virus (RSV). Its Fc region contains a triple amino acid substitution, which serves to improve its binding to the neonatal Fc receptor and extend its serum half-life. Administered as a single 105 mg intramuscular dose, irrespective of the infant’s weight, it delivers season-long protection against RSV, thereby supporting preventive healthcare for infants and populations deemed high-risk.

Which Companies Are Engaged In The Neutralizing Antibody Market Environment?

Major companies operating in the neutralizing antibody market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AstraZeneca PLC, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., GeNext Genomics, Celltrion Healthcare Co. Ltd, BeiGene Ltd, AbCellera Biologics Inc., BMC Pharmacology and Toxicology, Anthos Therapeutics, Immunome Inc., Sorrento Therapeutics Inc., Tonix Pharmaceuticals, Abwiz Bio, AXIM Biotechnologies.

Access The Complete Neutralizing Antibody Market Report:

https://www.thebusinessresearchcompany.com/report/neutralizing-antibody-global-market-report

Which Region Has The Strongest Presence In The Neutralizing Antibody Market?

North America was the largest region in the neutralizing antibody market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neutralizing antibody market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Neutralizing Antibody Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24620&type=smp

Browse Through More Reports Similar to the Global Neutralizing Antibody Market 2026, By The Business Research Company

Immune Health Supplements Market Report 2026

https://www.thebusinessresearchcompany.com/report/immune-health-supplements-global-market-report

Immunoglobulins Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Antibody Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibody-discovery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795